EHC - European Haemophilia Consortium/LinkedIn
Oct 1, 2025, 16:30
Emicizumab Approvals in Europe: European Haemophilia Consortium Shares Key Updates
European Haemophilia Consortium (EHC) posted on LinkedIn:
”Indications of non-factor treatments for haemophilia A are evolving.
In Europe, Emicizumab is approved for routine prophylaxis for moderate haemophilia A with severe bleeding, for severe haemophilia A and for haemophilia A with factor VIII inhibitors.
It is always a good idea to consult local regulatory authorities for the precise current approved use in your area.
Learn more in the EHCucate topic Emicizumab Basics, available on the EHC Academy.”
Stay updated with Hemostasis Today.
-
May 24, 2026, 17:48Flora Peyvandi: Crucial Role of Placental ADAMTS13 in Perinatal Survival
-
May 24, 2026, 17:13Mahtab Mashayekhi: The Evolving Role of Red Blood Cell Exchange in the Management of SCD
-
May 24, 2026, 17:12Silvina Graña: Helping Families Better Understand Hemophilia and Daily Life With Bleeding Disorders
-
May 24, 2026, 17:11Miikka Vikkula: Key Insights from the ISSVA 2026 World Congress
-
May 24, 2026, 17:10Mathieu Jackson: Proud to Be Present at This Historic Moment for the Global Bleeding Disorders Community
-
May 24, 2026, 17:09Ramina Fazeli: Highlighting the Emerging Role of Neutrophil Extracellular Traps in Ovarian Cancer
-
May 24, 2026, 16:12William Wallace: Normal B12 Levels May Still Cause Brain Damage and Cognitive Decline
-
May 24, 2026, 15:54Marc Carrier: Ottawa Race Weekend Raised Over 7,000 USD for Thrombosis Canada
-
May 24, 2026, 15:44Janak Sadhu: Building a Stroke-Free Mehsana Through Community Awareness and Healthcare Collaboration